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Liver kinase B1 (LKB1) genetic alteration in lung cancer involves not 
only point mutations and small deletion of several base pairs but also 
exonic loss. However, most of recent studies in LKB1 gene status only 
focus on point mutations and small deletion, and thus may underesti-
mate the actual frequency of LKB1 genetic alteration in lung cancer. 
Thus, an integrative analysis of LKB1 genetic alteration is timely and 
important for providing a better estimate for the incidence of genetic 
alterations in this important tumor suppressor gene. One hundred 
and seven lung adenocarcinomas with more than 70% tumor have 
been analyzed for mutation of LKB1 as well as LKB1 large deletions 
detection by using multiplex ligation-dependent probe amplification 
analysis. These samples were also analyzed for EGFR, KRAS, HER2, 
BRAF, ALK, ROS1, and RET status in stepwise method. Among 107 
lung adenocarcinomas analyzed, 29 (27.1%) harbored LKB1 genetic 
alteration. Twenty-three (21.5%) harbored LKB1 large exonic dele-
tions and eight (7.48%) had LKB1 points mutations, two samples 
harbored both LKB1 large exonic deletions and point mutations. 
 Eighty-seven samples (81.31%) harbored known driver mutations 
and 20 samples (18.69%) had no identifiable driver mutations. A 
high rate of LKB1 genetic alteration in Chinese lung adenocarci-
nomas is revealed by the integrative analysis of point mutation and 
exonic deletion. Moreover, LKB1 genetic alterations are concurrent 
with EGFR, KRAS, HER2, and CD74-ROS fusions.
Key Words: Liver kinase B1, Lung cancer, Multiplex ligation-
dependent probe amplification.
(J Thorac Oncol. 2014;9: 254–258)
Lung cancer is one of the most devastating diseases glob-ally, with the overall 5-year survival rate being about 
15%.1 In China, an estimated 400,000 patients die annually 
of lung cancer.2 Lung adenocarcinoma is the major subtype 
of lung cancer, accounting for approximately 40% of cases 
worldwide.3
Liver kinase B1 (LKB1), also known as STK11 or ser-
ine/threonine kinase 11, encodes a member of the serine/
threonine kinase family, and its germline mutation or dele-
tion results in partial loss of its function, which is considered 
to be responsible for benign polyp formation in Peutz–
Jehger’s syndrome (PJS).4,5 LKB1 regulates cell polarity and 
functions as a tumor suppressor.6 Somatic mutation of LKB1 
is frequently observed in lung cancer, which potentially con-
tributes to lung cancer malignancy progression and metasta-
sis.7 The frequency of LKB1 somatic mutation ranges from 
0.9% to 6.9% in lung adenocarcinomas for East Asians.8–10 
In contrast, the LKB1 mutation rate is about 17% to 42% 
in white population.11–13 Notably, most of these studies have 
been done to detect LKB1 point mutation or small deletion 
of several base pairs.11,13,14 However, as indicated by studies 
on LKB1 gene status detection in PJS patients, LKB1 genetic 
alteration can be caused not only by point mutations or short 
deletions, but also by exonic deletion of LKB1 or even loss 
of whole gene allele.15 Deletion of specific exon(s) of LKB1 
in tumor specimens, which could be routinely detected by 
multiplex ligation-dependent probe amplification (MLPA) 
assay, may not be detectable by genomic DNA sequenc-
ing because of the normal tissue contamination during the 
polymerase chain reaction (PCR) process. Thus, the use of 
a single method may significantly underestimate the actual 
rate of LKB1 genetic alterations in lung cancer.
By using MLPA to detect the LKB1 exonic deletion, 
we have integratively analyzed the actual LKB1 genetic 
alteration in 107 lung adenocarcinoma specimens. These 
samples were also analyzed for other major oncogenic 
driver mutations including EGFR, KRAS, HER2, BRAF 
mutations as well as ALK, ROS1, and RET fusions and the 
clinical relevance of these oncogenic mutations were also 
analyzed.
PATIENTS AND METHODS
The study was approved by the ethics review board 
at Fudan University Shanghai Cancer Center. All lung 
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adenocarcinomas were collected consecutively with written 
informed consents from all patients. Lung tumors were ana-
lyzed for LKB1 mutations as previously described.8 Total RNA 
and DNA were extracted from snap-frozen lung tumors or his-
tological normal lung from distant area as standard protocol 
(Qiagen, Duesseldorf, Germany). The status of oncogenic 
driver mutations was determined as previously described.8 
MLPA was performed in accordance with the instruction 
book by using the SALSA MLPA kit P101-B1 STK11 (MRC-
Holland, Amsterdam, The Netherlands).
RESULTS
Patient Characteristics
From October 2007 to January 2010, we collected 107 
resected lung adenocarcinoma specimens, which on histologi-
cal analysis by pathologists were shown to contain more than 
70% tumors. Fifty-two tumors were from never smokers and 
55 from smokers. The number of patients in stages I to IV was 
48, 13, 45, and 1, respectively.
LKB1 Genetic Alteration in Chinese 
Lung Adenocarcinomas
Our previous study using direct sequencing of genomic 
DNA in 86 lung adenocarcinoma specimens have identified six 
samples with LKB1 somatic mutations.8 Because this type of 
analysis could not detect exonic deletion of LKB1, we performed 
molecular analysis with MLPA assay, as previously described in 
study of PJS.15
Strikingly, we found that 23 patients (21.5%) had LKB1 
exonic deletions (Fig. 1), among which 16 tumors harbored a 
specific deletion of exon 1. One tumor harbored a deletion of 
exon 8. One tumor harbored a deletion of exon 1 to exon 3. 
Another four samples had the deletion of exon 1 to exon 4. 
One sample had the deletion of the whole gene from the pro-
moter to exon 9. Besides, we found eight tumors harbor LKB1 
somatic mutations and two of them also have LKB1 exonic 
deletions. This integrative analysis with the combination of 
direct sequencing and MLPA analysis of genomic DNA results 
have uncovered a high rate of LKB1 genetic alteration (27.1%; 
29 of 107) in Chinese lung adenocarcinomas. Clinical rele-
vance analysis revealed that there was no statistically signifi-
cant difference for clinical pathological features (Table 1). The 
genetic alterations of LKB1 include certain known missense, 
nonsense mutations and small piece deletions,16–18 splicing 
site mutations, and exonic deletions (Table 2). Further real-
time PCR confirmed the exonic deletion of LKB1 exon 1 in 
all the 18 samples (Supplementary Figure 1, Supplemental 
Digital Content, http://links.lww.com/JTO/A532).
Oncogenic Driver Mutations in 
Chinese Lung Adenocarcinomas
The oncogenic driver mutants potentially provide ideal 
targets for lung cancer treatment in clinic and we checked 
the status of known driver mutations in the cohort. We found 
62.62% (67 of 107) of tumors harbored EGFR kinase domain 
mutations whereas only 5.61% (6 of 107) had KRAS muta-
tions;8 2.8% (3 of 107) of samples had HER2 exon 20 inser-
tions mutations. BRAF mutations were detected in 2.8% 
(3 of 107) of samples, including two V600E mutations and 
one D594G mutation. 1.87% (2 of 107) of patients harbored 
ROS1 fusions, which both fused to CD74; 4.67% (5 of 107) 
FIGURE 1. LKB1 deletions in Chinese lung adenocarcinomas by MLPA. Seventeen probes (white) correspond to LKB1 locus on 
chromosome 19. Probes 0.92M 5', 0.66M5' 0.28M 5', and 0.35M 5' are about 920, 660, 280, and 350 kb 5' of locus (telo-
meric), whereas 10M 3' is about 10,000 kb 3' (centromeric). There are three probes for exon 1 and one probe each for other 
nine exons. Black bars correspond to randomly selected probes from other chromosomes. Sample 181 does not have deletion, 
sample 385 shows exon 1 deletion and sample 249 shows whole LKB1 locus deletion. There are three lines corresponding to 0.7 
(green), one (yellow), and 1.3 (red) relative signal intensity. Bars=relative signal intensity per probe.
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of samples were found to have EML4-ALK fusions, involving 
EML4 exons 13, 20, and 6 ligated to ALK exon 19 (variant 1, 
2, 3a/b). 0.93% (1of 107) of patients harbored CCDC6-RET 
fusion.8 Overall, 18.69% (20 of 107) of samples had no iden-
tifiable driver mutations. Spectrum of oncogenic driver muta-
tions in lung adenocarcinomas is shown in Figure 2.
We further analyzed the correlations between driver 
mutations and LKB1 genetic alterations (Table 3, Fig. 3). 
Surprisingly, 18 samples with LKB1 genetic alterations have 
TABLE 1.  Association between LKB1 Genetic Alterations 
and Clinical Pathological Features in Chinese Lung 
Adenocarcinoma Patients
Variable Total Positive, n(%) Negative, n(%) p
n 107 29(27.1) 78(72.9) –
Age
  <60 62 19(30.6) 43(69.4) 0.333
  ≥60 45 10(22.2) 35(77.8) –
Sex
  Male 64 16(25) 48(75) 0.55
  Female 43 13(30.2) 30(69.8) –
Smoking status
  Never smoker 52 16(30.8) 36(69.2) 0.407
  Smoker 55 13(23.6) 42(76.4) –
Differentiation
  Well to moderate 70 21(30) 49(70) 0.354
  Poor 37 8(21.6) 29(78.4)
Stage
  I/II 61 18(29.5) 43(70.5) 0.519
  III/IV 46 11(23.9) 35(76.1)
TABLE 2.  Description and Frequency of LKB1 Genetic 
Alterations
Description n (%) Type of alteration
Mutation
  IVS4-1G>T 1 (0.93) Splicing site mutation
  536C>T (P179L) 1 (0.93) Missense mutation
  658C>T (Q220stop) 1 (0.93) Nonsense mutation
  148_159del12 
(del50L_53D)
1 (0.93) 12bp deletion
  IVS5-1G>Ta 1 (0.93) Splicing site mutation
  IVS5-1G>Ta 1 (0.93) Splicing site mutation
  375G>A(M125I) 1 (0.93) Missense mutation
  387G>A(M129I), 
388G>T(E130stop)
1 (0.93) Missense mutation/ 
nonsense mutation
  580G>T(D194Y)a 1 (0.93) Missense mutation
Deletion
  Exon 1 16 (14.95) Exonic deletion
  Exon 8 1 (0.93) Exonic deletion
  Exon 1 to exon 3 1(0.93) Exonic deletion
  Exon 1 to exon 4 4 (3.74) Exonic deletion
  Promoter to exon 9 1(0.93) Exonic deletion
aHave been reported previously.
FIGURE 2.  Spectrum of oncogenic driver mutations in 
Chinese lung adenocarcinomas. Among 107 lung adenocarci-
nomas analyzed, 67 samples (62.62%) harbored EGFR muta-
tions, six samples (5.61%) harbored KRAS mutations, three 
samples (2.8%) harbored HER2 mutations, and three samples 
(2.8%) had BRAF mutations. Five samples (4.67%) had 
EML4-ALK fusions, two samples (1.87%) harbored  CD74-ROS1 
fusions and one (0.93%) harbored CCDC6-RET fusion. There 
are 20 samples (18.69%) with unknown oncogenic driver 
mutations.
TABLE 3.  Association between LKB1 Genetic Alterations and 
Driver Mutations
Variable Total Positive, n(%) Negative, n(%) p
n 107 29(27.1) 78(72.9) –
EGFR
  Wild type 40 11(27.5) 29(72.5) 0.943
  Mutation 67 18(26.9) 49(73.1)
KRAS
  Wild type 101 25(24.8) 76(75.2) 0.045a 
  Mutation 6 4(66.7) 2(33.3)
ALK
  Wild type 102 29(28.4) 73(71.6) 0.32a
  Mutation 5 0(0) 5(100)
HER2
  Wild type 104 28(26.9) 76(73.1) 1a
  Mutation 3 1(33.3) 2(66.7)
BRAF
  Wild type 104 29(27.9) 75(72.1) 0.561a 
  Mutation 3 0(0) 3(100)
ROS
  Wild type 105 28(26.7) 77(73.3) 0.47a
  Mutation 2 1(50) 1(50)
RET
  Wild type 106 29(27.4) 77(72.6) 1a
  Mutation 1 0(0) 1(100)
aFisher’s exact test.
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concurrent EGFR mutations, which were previously consid-
ered as mutually exclusive events. Six cases with LKB1 genetic 
alteration also had: KRAS (4), HER2 mutation (1), and ROS1 
fusion (1). We have observed that all five lung adenocarci-
nomas positive for EML4-ALK fusions, one  CCDC6-RET 
fusion and three BRAF mutations did not have LKB1 genetic 
alterations, suggesting a pattern of mutual exclusivity between 
LKB1 genetic alterations and EML4-ALK, CCDC6-RET 
fusions and BRAF mutations (Fig. 3). Interestingly, LKB1 
genetic alterations are significantly correlated with KRAS 
mutations (Table 3).
DISCUSSION
Previous studies have demonstrated that LKB1 somatic 
mutation is much lower in East Asian population in compari-
son with white population. However, with the inclusion of the 
exonic deletion of LKB1 gene allele, we have shown here that 
27.1% (29 of 107) of Chinese lung adenocarcinomas harbored 
LKB1 genetic alterations. Through integrative genomic stud-
ies, we have, for the first time, demonstrated that inactivation 
of LKB1 gene allele in lung cancer either by somatic muta-
tions or exonic deletions are not rare genetic events in Chinese 
lung adenocarcinomas.
The rate of LKB1 mutation and exonic deletion in this 
study were 7.47% (8 of 107) and 21.5% (23 of 107) respectively, 
highlighting the prevalence of LKB1 large fragment deletion 
over LKB1 point mutations in Chinese lung adenocarcinoma 
patients. Weir et al.19 did not detect a high prevalence of LKB1 
gene mutation in 371 samples of lung adenocarcinoma. This 
suggests that perhaps this gene is more prevalent in adenocar-
cinoma in Asian population as opposed to white population. 
As a tumor suppressor, LKB1 expression is frequently low in 
tumor samples. The use of cDNA as template for PCR sequenc-
ing may preferentially amplify LKB1 from contaminated normal 
tissues, which may require more sensitive sequencing methods 
like  SURVEYOR-WAVE than regular Sanger sequencing.11 The 
differential expression pattern of LKB1 in tumors and normal 
lungs may not affect the results from genomic DNA sequenc-
ing; however, this method may still not be able to detect LKB1 
exonic deletions. This method requires a high tumor rate as well 
as a high genomic DNA quality. In our study, we have used the 
specimens with over 70% tumor rate. The integrative analyses of 
somatic mutations and exonic deletion will theoretically give us 
the actual rate of LKB1 genetic alteration. The high frequency 
of LKB1 genetic alteration (27.1%) in lung adenocarcinomas 
highlights the importance of LKB1 as tumor suppressor genes in 
lung cancer. Moreover, our data have shown that LKB1 genetic 
alterations are concurrent with EGFR kinase domain mutations, 
which seems to contradict a previous report.8 It is worth not-
ing that a majority of the LKB1 genetic alterations concurrent 
with EGFR mutations in this study are derived from exonic loss, 
which has not been analyzed by that previous study.8 Consistent 
with this previous report,16 we also find that LKB1 genetic alter-
ations significantly correlate with KRAS mutations. Besides, 
LKB1 genetic alterations are mutually exclusive with EML4-
ALK,  CCDC6-RET fusions, and BRAF mutations. Future work 
is necessary to clarify why this happens.
In summary, we have uncovered an unexpectedly high 
frequency of LKB1 genetic alterations in Chinese lung ade-
nocarcinomas through integrative analysis of LKB1 somatic 
mutations as well as exonic deletions and revealed its interest-
ing correlation with driver mutations. Our study provides an 
example for future assessing of LKB1 genetic alterations in 
lung cancers as well as other types of cancers.
ACKNOWLEDGMENTS
The authors thank Junhua Zhang, Shihua Yao, Yayun 
Chi, and Xiaolei Ye for technical support.
This work was supported by the National Basic Research 
Program of China (2012CB910800 and 2010CB912102), the 
National Natural Science Foundation of China (81101583, 
81372509, 31370747 and 30971461), the Science and Technology 
Commission of Shanghai Municipality (12JC1409800), the 
SA-SIBS scholarship program (HL and HJ).
REFERENCES
 1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer 
statistics. CA Cancer J Clin 2011;61:69–90.
 2. Yang L, Yang G, Zhou M, et al. Body mass index and mortality 
from lung cancer in smokers and nonsmokers: a nationally repre-
sentative prospective study of 220,000 men in China. Int J Cancer 
2009;125:2136–2143.
 3. Ginsberg MS, Grewal RK, Heelan RT. Lung cancer. Radiol Clin North 
Am 2007;45:21–43.
 4. Osoegawa A, Kometani T, Nosaki K, et al. LKB1 mutations frequently 
detected in mucinous bronchioloalveolar carcinoma. Jpn J Clin Oncol 
2011;41:1132–1137.
 5. Hemminki A, Markie D, Tomlinson I, et al. A serine/threonine kinase 
gene defective in Peutz-Jeghers syndrome. Nature 1998;391:184–187.
 6. Sanchez-Cespedes M. A role for LKB1 gene in human cancer beyond the 
Peutz-Jeghers syndrome. Oncogene 2007;26:7825–7832.
 7. Gao Y, Xiao Q, Ma H, et al. LKB1 inhibits lung cancer progression 
through lysyl oxidase and extracellular matrix remodeling. Proc Natl 
Acad Sci U S A 2010;107:18892–18897.
 8. Gao B, Sun Y, Zhang J, et al. Spectrum of LKB1, EGFR, and KRAS 
mutations in chinese lung adenocarcinomas. J Thorac Oncol 
2010;5:1130–1135.
 9. Koivunen JP, Kim J, Lee J, et al. Mutations in the LKB1 tumour suppres-
sor are frequently detected in tumours from Caucasian but not Asian lung 
cancer patients. Br J Cancer 2008;99:245–252.
 10. Kim MJ, Jin G, Jheon HS, et al. LKB1 mutations are extremely rare 
in Korean non-small cell lung cancers. Cancer Genet Cytogenet 
2010;196:204–206.
 11. Koivunen JP, Kim J, Lee J, et al. Mutations in the LKB1 tumour suppres-
sor are frequently detected in tumours from Caucasian but not Asian lung 
cancer patients. Br J Cancer 2008;99:245–252.
FIGURE 3.  Concurrent and mutual exclusion of muta-
tions observed across genes in Chinese lung adenocarci-
nomas. Tumors (columns) with or without mutations are 
labeled in red or green for each gene (row) indicated, 
respectively. Tumors from older patients (≥60 years) and 
younger patients (<60 years) are labeled in brown and pink, 
respectively.
258 Copyright © 2013 by the International Association for the Study of Lung Cancer
Fang et al. Journal of Thoracic Oncology ®  •  Volume 9, Number 2, February 2014
 12. Sanchez-Cespedes M, Parrella P, Esteller M, et al. Inactivation of LKB1/
STK11 is a common event in adenocarcinomas of the lung. Cancer Res 
2002;62:3659–3662.
 13. Matsumoto S, Iwakawa R, Takahashi K, et al. Prevalence and specificity of 
LKB1 genetic alterations in lung cancers. Oncogene 2007;26:5911–5918.
 14. Onozato R, Kosaka T, Achiwa H, et al. LKB1 gene mutations in Japanese 
lung cancer patients. Cancer Sci 2007;98:1747–1751.
 15. Chow E, Meldrum CJ, Crooks R, Macrae F, Spigelman AD, Scott RJ. An 
updated mutation spectrum in an Australian series of PJS patients provides 
further evidence for only one gene locus. Clin Genet 2006;70:409–414.
 16. Matsumoto S, Iwakawa R, Takahashi K, et al. Prevalence and 
specificity of LKB1 genetic alterations in lung cancers. Oncogene 
2007;26:5911–5918.
 17. Hearle N, Schumacher V, Menko FH, et al. Frequency and spec-
trum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res 
2006;12:3209–3215.
 18. Guldberg P, thor Straten P, Ahrenkiel V, Seremet T, Kirkin AF, Zeuthen J. 
Somatic mutation of the Peutz-Jeghers syndrome gene, LKB1/STK11, in 
malignant melanoma. Oncogene 1999;18:1777–1780.
 19. Weir BA, Woo MS, Getz G, et al. Characterizing the cancer genome in w
